T2 Biosystems is an in vitro diagnostics company. Co. has developed a proprietary technology platform that provides an alternative to existing diagnostic methodologies. Co. has received market clearance from the U.S. Food and Drug Administration (the FDA) for its two products, the T2Dx® Instrument and the T2Candida® Panel, which have the ability to identify the five clinically relevant species of Candida, a fungal pathogen known to cause sepsis, directly from whole blood. In addition, Co. has received market clearance from the FDA for the T2Bacteria® Panel, which runs on the T2Dx Instrument and has the ability to identify five of the sepsis-causing bacteria directly from whole blood. The TTOO stock yearly return is shown above.
The yearly return on the TTOO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TTOO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|